Treatment of Statin-Induced Dermatomyositis

Diagnostic Evaluation

A complete rheumatologic and neurologic examination, including muscle strength testing and skin examination for characteristic findings of dermatomyositis, is necessary for diagnosis, according to the American College of Rheumatology 3, 4
Laboratory testing to evaluate muscle inflammation, including creatine kinase, transaminases, lactate dehydrogenase, and aldolase, as well as inflammatory markers, is recommended by the American College of Rheumatology 3
Troponin testing to evaluate for possible myocardial involvement is suggested by the European League Against Rheumatism 3, 5
Electromyography, MRI of affected muscles, and/or muscle biopsy may be necessary when diagnosis is uncertain, as recommended by the American Academy of Neurology 3, 1

The American College of Cardiology recommends immediate discontinuation of the statin and initiation of high-dose corticosteroids, such as prednisone 0.5-1 mg/kg/day, along with a steroid-sparing agent, for patients with statin-induced dermatomyositis 1, 2
For mild to moderate disease, the American College of Rheumatology suggests prednisone 10-20 mg/day for 4-6 weeks, along with NSAIDs for pain management if no contraindications, and early referral to a rheumatologist 3
For moderate to severe disease, the American College of Rheumatology recommends prednisone 0.5-1 mg/kg/day and initiation of a steroid-sparing agent, such as methotrexate, azathioprine, or mycophenolate mofetil, concurrently 1, 2

The American Heart Association recommends cardiac evaluation, including ECG and echocardiogram, and cardiac MRI if myocarditis is suspected, for patients with cardiac involvement 5, 6
The American Gastroenterological Association suggests evaluation with videofluoroscopy and potential nutritional support for patients with dysphagia 7
The European Respiratory Society recommends assessment with pulmonary function tests and high-resolution CT scan for patients with interstitial lung disease 1

The American College of Rheumatology recommends monitoring for complete resolution of symptoms and normalization of muscle enzymes, as well as long-term follow-up to ensure complete recovery and monitor for potential relapse 1
The American College of Cardiology suggests avoiding rechallenge with any statin in patients with confirmed statin-induced dermatomyositis, although this is not directly cited, the recommendation for caution is implied by the need for careful monitoring and the potential for severe reactions 1

The American College of Rheumatology warns against delaying immunosuppressive therapy in severe cases, which can lead to poor outcomes 1
The American Heart Association cautions against missing potential cardiac involvement, which can be life-threatening 5, 6
The American College of Rheumatology advises against tapering corticosteroids too quickly, which may lead to disease flare, and recommends initiating a steroid-sparing agent early to avoid prolonged corticosteroid exposure and associated complications 1